Hereditary Angioedema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Prophylaxis is the fastest growing sector, North America is the largest market

The global Hereditary Angioedema (HAE) therapeutics market is projected to expand significantly, increasing from USD 4.41 billion in 2025 to USD 7.36 billion by 2031, demonstrating an 8.91% compound annual growth rate. These specialized pharmaceutical interventions are designed to address C1-inhibitor deficiency and include acute treatments for sudden attacks as well as prophylactic agents to lessen the frequency of swelling. Key drivers for this market include the enhanced identification of previously undiagnosed individuals and a growing preference for convenient oral preventative treatments over injectable options. Furthermore, supportive reimbursement policies in developed economies continue to improve patient access to these vital biologic and small-molecule medications.

Despite this projected growth, the market contends with considerable challenges, particularly extensive diagnostic delays that often result in prolonged periods of untreated HAE for a significant portion of the patient population. Misdiagnosis presents a critical obstacle, as HAE symptoms are frequently mistaken for common allergic reactions, thereby restricting the effective utilization of available therapies. As an indicator of current accessibility, HAE International reported in 2024 that 78% of its member organizations had access to at least one hereditary angioedema medication. This highlights that while therapeutic availability is improving, inconsistent access remains a barrier to realizing the market's full potential.

Market Drivers

A primary market driver is the fundamental shift from on-demand treatment to long-term prophylaxis, significantly supported by the increasing adoption of patient-friendly oral administration methods. Both patients and physicians are increasingly favoring preventative regimens that effectively reduce attack frequency and ease the burden of administration compared to traditional injectable acute therapies, thereby markedly enhancing the quality of life. This strategic transition is commercially evident, rapidly transforming revenue streams within the sector. BioCryst Pharmaceuticals reported in November 2024 that ORLADEYO's net revenue reached $116.3 million in the third quarter of 2024, marking a 35.7% year-over-year increase and underscoring robust patient demand for oral prophylactic options over older treatments.

Concurrently, the market is propelled by a robust clinical pipeline featuring next-generation biologics and gene therapies, which are being developed to offer durable and potentially curative outcomes. Innovations such as in vivo CRISPR-based editing are progressing through clinical stages with promising efficacy profiles, poised to redefine standard care by potentially eliminating the need for chronic dosing. Illustrating this advancement, Intellia Therapeutics noted in October 2024 that a single 50 mg dose of NTLA-2002 resulted in an 81% mean monthly attack rate reduction compared to placebo during weeks 5 through 16 of its Phase 2 study. The commercial sector also remains dynamic; Pharming Group N.V. reported in 2024 a 12% increase in total third-quarter revenues to US$74.8 million, reflecting sustained economic momentum across the global therapeutic landscape.

Market Challenges

The foremost impediment to the growth of the Global Hereditary Angioedema Therapeutics Market remains the persistent issue of diagnostic delays and widespread misdiagnosis. Since HAE symptoms closely resemble common histaminergic allergic reactions, frontline healthcare providers often fail to accurately identify the condition, frequently prescribing ineffective antihistamines or corticosteroids instead of the necessary targeted therapies. This confusion at the initial point of care severely limits the conversion of the potential patient population into active consumers of HAE therapeutics. Consequently, pharmaceutical companies face a significant barrier where the addressable market is artificially suppressed, as a large number of patients cannot access or purchase these specialized biologic and small-molecule drugs simply because their condition has not been correctly identified.

The sheer scale of this diagnostic gap is further emphasized by recent data, which highlights how many patients remain unrecognized by the healthcare system. According to HAE International, the diagnosis rate for the condition was reported to be merely 53% in 2024. This statistic indicates that almost half of the potential patient base remains undiagnosed and, consequently, unreachable for therapeutic intervention. Until these critical diagnostic bottlenecks are effectively resolved, the market will continue to operate substantially below its full revenue potential, unable to fully capitalize on the demand from a significant segment of the population requiring these life-altering prophylactic and acute treatments.

Market Trends

The commercialization of RNA-targeted therapies signifies a precise evolution in prophylactic care, moving beyond protein replacement to upstream inhibition of prekallikrein synthesis. Unlike conventional C1-esterase inhibitors, these antisense oligonucleotides function by silencing the specific mRNA responsible for the disease pathway, offering a novel mechanism for patients who are unresponsive to standard treatments or those seeking less frequent dosing intervals. This therapeutic class effectively achieves a significant reduction in attack frequency, thereby validating the potential of RNA interference to redefine standard management protocols. Ionis Pharmaceuticals reported in May 2024 from the Phase 3 OASIS-HAE Study that patients treated with the investigational RNA-targeted medicine, donidalorsen, experienced an 87% reduction in mean monthly attack rates compared to placebo, underscoring the robust efficacy of this emerging modality.

Simultaneously, the development of extended half-life biologics continues to capture significant market share, maintaining its relevance despite the increasing availability of oral alternatives. While oral regimens offer convenience, monoclonal antibodies that target plasma kallikrein provide sustained, high-efficacy control for patients who prioritize maximum attack prevention over the administration route. This segment is expanding through formulations that enable less frequent subcutaneous dosing, ensuring long-term adherence and stability for the most severe cases. The economic resilience of this category is substantial; Takeda Pharmaceutical Company Limited reported in October 2024 that revenue for its subcutaneous prophylactic treatment, Takhzyro, grew to 95.3 billion JPY in the first half of fiscal year 2024, demonstrating persistent demand for established injectable biologics amid a diversifying competitive landscape.

Key Market Players

• Takeda Pharmaceutical Company Limited
• CSL Behring LLC
• BioCryst Pharmaceuticals, Inc.
• Pharming Group N.V.
• Ionis Pharmaceuticals, Inc.
• KalVista Pharmaceuticals, Inc.
• Intellia Therapeutics, Inc.
• Astria Therapeutics, Inc.
• Alnylam Pharmaceuticals, Inc.
• Novartis AG

Report Scope

In this report, the Global Hereditary Angioedema Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hereditary Angioedema Therapeutics Market, by Drug Class:

• C1 Esterase Inhibitor
• Selective Bradykinin B2 Receptor Antagonist
• Kallikrein Inhibitor
• Other Drug Classes

Hereditary Angioedema Therapeutics Market, by Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Other Distribution Channels

Hereditary Angioedema Therapeutics Market, by Application:

• Prophylaxis
• On-demand

Hereditary Angioedema Therapeutics Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hereditary Angioedema Therapeutics Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.